Ketamine attenuates and reverses morphine tolerance in rodents

Anesthesiology

Volumn 85, Issue 6, 1996, Pages 1357-1366

  Shimoyama, Naohito ^a   Shimoyama, Megumi ^a   Inturrisi, Charles E ^b   Elliott, Kathryn J ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Analgesics, opioid: morphine; Antagonist, N methyl D aspartate: ketamine; Receptor: N methyl D aspartate; Tolerance

Indexed keywords

KETAMINE; MORPHINE SULFATE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ARTICLE; CHRONIC PAIN; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG TOLERANCE; INTRASPINAL DRUG ADMINISTRATION; MALE; MORPHINE ADDICTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TAIL FLICK TEST;

ANALGESIA; ANALGESICS, OPIOID; ANESTHETICS, DISSOCIATIVE; ANIMALS; DRUG TOLERANCE; INJECTIONS, SPINAL; INJECTIONS, SUBCUTANEOUS; KETAMINE; MALE; MICE; MORPHINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0030470420     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-199612000-00017     Document Type: Article

References (50)

1. Trujillo KA, Akil H: Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 1991; 251:85-7
2. Elliott K, Minami N, Kolesnikov YA, Pasternak GW, Inturrisi CE: The NMDA receptor antagonists, LY274614 and MK-801, and the nitric oxide synthase inhibitor, NG-nitro-L-arginine, attenuate analgesic tolerance to the mu-opioid morphine but not to kappa opioids. Pain 1994; 56:69-75
3. Marek P, Ben-Eliyahu S, Gold M, Liebeskind JC: Excitatory amino acid antagonists (kynurenic acid and MK-801) attenuate the development of morphine tolerance in the rat. Brain Res 1991; 547:77-81
4. Tiseo PJ, Inturrisi CE: Attenuation and reversal of morphine tolerance by the competitive N-methyl-D-aspartate receptor antagonist, LY274614. J Pharmacol Exp Ther 1993; 264:1090-6
5. Tiseo PJ, Cheng J, Pasternak GW, Inturrisi CE: Modulation of morphine tolerance by the competitive N-methyl-D-aspartate receptor antagonist LY274614: Assessment of opioid receptor changes. J Pharmacol Exp Ther 1994; 268:195-201
6. Elliott K, Hynansky A, Inturrisi CE: Dextromethorphan attenuates and reverses analgesic tolerance to morphine. Pain 1994; 59:361-8
7. Brodsky M, Elliott K, Hynansky A, Minami N, Inturrisi CE: NMDA receptor and proenkephalin gene expression are modulated by chronic morphine administered alone or in combination with NMDA antagonist (Abstract). Soc Neurosci 1993; 19:1352
8. Church J, Lodge D: N-methyl-D aspartate (NMDA) antagonism is central to the actions of ketamine and other phencyclidine receptor ligands, Status of Ketamine in Anesthesiology. Edited by EF Domino. Ann Arbor, NPP Books, 1990, pp 501-19
9. Anis NA, Berry SC, Burton NR, Lodge D: The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br J Pharmacol 1983; 79:565-75
10. Martin D, Lodge D: Ketamine acts as a non-competitive N-methyl-D-aspartate antagonist on frog spinal cord in vitro. Neuropharmacology 1985; 24:999-1003
11. MacDonald JF, Miljkovic Z, Pennefather P: Use-dependent block of excitatory amino acid currents in cultured neurons by ketamine. J Neurophysiol 1987; 58:251-66
12. O'Shaughnessy CT, Lodge D: N-methyl-D-aspartate receptor-mediated increase in intracellular calcium is reduced by ketamine and phencyclidine. Eur J Pharmacol 1988; 153:201-9
13. Trujillo KA, Akil H: Inhibition of opiate tolerance by non-competitive N-methyl-D-aspartate receptor antagonists. Brain Res 1994; 633:178-88
14. Yaksh TL, Rudy TA: Chronic catheterization of the spinal subarachnoid space. Physiol Behav 1976; 17:1031-6
15. Umans JG, Inturrisi CE: Pharmacodynamics of subcutaneously administered diacetylmorphine, 6-acetylmorphine and morphine in mice. J Pharmacol Exp Ther 1981; 218:409-15
16. Stevens CW, Yaksh TL: Time course characteristics of tolerance development to continuously infused antinociceptive agents in rat spinal cord. J Pharmacol Exp Ther 1989; 251:216-23
17. Chen L, Huang LY: Sustained potentiation of NMDA receptor-mediated glutamate responses through activation of protein kinase C by a μ opioid. Neuron 1991; 7:319-26
18. 2+ block of NMDA-receptor channels as a mechanism of modulation. Nature 1992; 356:521-3
19. Welch SP, Olson KG: Opiate tolerance-induced modulation of free intracellular calcium in synaptosomes. Life Sci 1991; 48:1853-61
20. Kolesnikov YA, Pick CG, Pasternak GW: NG-nitro-L-arginine prevents morphine tolerance. Eur J Pharmacol 1992; 221:399-400
21. Kolesnikov YA, Pick CG, Ciszewska G, Pasternak GW: Blockade of tolerance to morphine but not kappa opioids by a nitric oxide synthase inhibitor. Proc Natl Acad Sci USA 1993; 90:5162-6
22. Mayer DJ, Mao J, Price DD: The development of morphine tolerance and dependence is associated with translocation of protein kinase C. Pain 1995; 61:365-74
23. Bhargava HN, Reddy PL, Gudehithlu KP: Down-regulation of N-methyl-D-aspartate (NMDA) receptors of brain regions and spinal cord of rats treated chronically with morphine. Gen Pharmacol 1995; 26:131-6
24. Gutstein HB, Trujillo KA: MK-801 inhibits the development of morphine tolerance at spinal sites. Brain Res 1993; 626:332-4
25. Kest B, Mogil JS, Ben-Eliyahu S, Kao B, Liebeskind JC, Marek P: The NMDA receptor antagonist MK-801 protects against the development of morphine tolerance after intrathecal administration. Proc West Pharmacol Soc 1993; 36:307-10
26. Mao J, Price DD, Mayer DJ: Thermal hyperalgesia in association with the development of morphine tolerance in rats: Roles of excitatory amino acid receptors and protein kinase C. J Neurosci 1994; 14:2301-12
27. Cohen ML, Trevor AJ: On the cerebral accumulation of ketamine and the relationship between metabolism of the drug and its pharmacological effects. J Pharmacol Exp Ther 1974; 189:351-8
28. Ren K, Williams GM, Hylden JLK, Ruda MA, Dubner R: The intrathecal administration of excitatory amino acid receptor antagonists selectively attenuated carrageenan-induced behavioral hyperalgesia in rats. Eur J Pharmacol 1992; 219:235-43
29. Yamamoto T, Yaksh TL: Spinal pharmacology of thermal hyperesthesia induced by constriction injury of sciatic nerve. Excitatory amino acid antagonists. Pain 1992; 49:121-8
30. Mao J, Price DD, Hayes RL, Lu J, Mayer DJ, Frenk H: Intrathecal treatment with dextrorphan or ketamine potently reduces pain-related behaviors in a rat model of peripheral mononeuropathy. Brain Res 1993; 605:164-8
31. Huettner JE, Bean BP: Block of N-methyl-D-aspartate-activated current by the anticonvulsant MK-801: selective binding to open channels. Proc Natl Acad Sci USA 1988; 85:1307-11
32. Lipton SA, Rosenberg PA: Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994; 330:613-22
33. Sadove MS, Shulman M, Hatano S, Fevold N: Analgesic effects of ketamine administered in subdissociative doses. Anesth Analg 1971; 50:452-7
34. Slogoff S, Allen GW, Wessels JV, Cheney DH: Clinical experience with subanesthetic ketamine. Anesth Analg 1974; 53:354-8
35. Maurset A, Skoglund LA, Hustveit O, Øye I: Comparison of ketamine and pethidine in experimental and postoperative pain. Pain 1989; 36:37-41
36. Eide PK, Jørum E, Stubhaug A, Bremnes J, Breivik H: Relief of post-herpetic neuralgia with the N-methyl-D-aspartic acid receptor antagonist ketamine: A double-blind, cross-over comparison with morphine and placebo. Pain 1994; 58:347-54
37. Backonja M, Arndt G, Gombar KA, Check B, Zimmermann M: Response of chronic neuropathic pain syndromes to ketamine: A preliminary study. Pain 1994; 56:51-7
38. Max MB, Byas-Smith MG, Gracely RH, Bennett GJ: Intravenous infusion of the NMDA antagonist, ketamine, in chronic posttraumatic pain with allodynia: A double-blind comparison to alfentanil and placebo. Clin Neuropharmacol 1995; 18:360-8
39. Oshima E, Tei K, Kayazawa H, Urabe N: Continuous subcutaneous injection of ketamine for cancer pain. Can J Anaesth 1990; 37:385-6
40. Clark JL, Kalan GE: Effective treatment of severe cancer pain of the head using low-dose ketamine in an opioid-tolerant patient. Journal of Pain Symptom Management 1995; 10:310-14
41. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS: Subanesthetic effects of noncompetitive NMDA antagonist, ketamine, in humans. Arch Gen Psychiatry 1994; 51:199-214
42. Cartwright PD, Pingel SM: Midazolam and diazepam in ketamine anaesthesia. Anaesthesia 1984; 39:439-42
43. White PF, Ham J, Way WL, Trevor AJ: Pharmacology of ketamine isomers in surgical patients. Anesthesiology 1980; 52:231-9
44. Olney JW, Labruyere J, Price MT: Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 1989; 244:1360-2
45. Corssen G, Oget S: Dissociative anesthesia for the severely burned child. Anesth Analg 1971; 50:95-102
46. Demling RH, Ellerbe S, Jarrett F: Ketamine anesthesia for tangential excision of burn eschar: A burn unit procedure. J Trauma 1978; 18:269-70
47. Cederholm I, Bengtsson M, Björkman S, Choonara I, Rane A: Long term high dose morphine, ketamine and midazolam infusion in a child with burns. Br J Clin Pharmacol 1990; 30:901-5
48. Borgbjerg FM, Svensson BA, Frigast C, Gordh T: Histopathology after repeated intrathecal injections of preservative-free ketamine in the rabbit: A light and electron microscopic examination. Anesth Analg 1994; 79:105-11
49. Brock-Utne JG, Kallichurum S, Mankowitz E, Maharaj RJ, Downing JW: Intrathecal ketamine with preservative - Histological effects on spinal nerve roots of baboons. S Afr Med J 1982; 61:440-1
50. Bion JF: Intrathecal ketamine for war surgery. A preliminary study under field conditions. Anaesthesia 1984; 39:1023-8